Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 9, 2014, Pages 3216-3228

  Falamarzian, Arash ^a   Montazeri Aliabadi, Hamidreza ^a   Molavi, Ommoleila ^b   Seubert, John M ^a   Lai, Raymond ^b   Uludaǧ, Hasan ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

chemotherapy; hydrophobic modification; polycationic polymers; siRNA; STAT3

Indexed keywords

CELL DEATH; CHEMOTHERAPY; CYTOTOXICITY; DISEASES; LINOLEIC ACID; MOLECULAR WEIGHT; POLYMERS; RNA; TRANSCRIPTION; TRANSDUCERS;

CHEMOTHERAPEUTIC AGENTS; CHEMOTHERAPEUTIC DRUGS; HYDROPHOBIC MODIFICATION; INHIBITION OF TUMOR GROWTH; LOW MOLECULAR WEIGHT; POLYCATIONIC POLYMERS; SIRNA; STAT3;

TUMORS;

DOXORUBICIN; LINOLEIC ACID; LIPID; MESSENGER RNA; OCTANOIC ACID; OLEIC ACID; PACLITAXEL; POLYETHYLENEIMINE DERIVATIVE; SMALL INTERFERING RNA; STAT3 PROTEIN; STEARIC ACID; ANTINEOPLASTIC AGENT; POLYETHYLENEIMINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CELL DEATH; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMOSENSITIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; FLUORESCENCE MICROSCOPY; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MONOTHERAPY; NONVIRAL GENE DELIVERY SYSTEM; PHENOTYPE; TRIPLE NEGATIVE BREAST CANCER; WILD TYPE; ANALOGS AND DERIVATIVES; BREAST; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PACLITAXEL; POLYETHYLENEIMINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 84904814325     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34992     Document Type: Article

References (60)

1. Schust J, Sperl B, Hollis A, Mayer TU, Berg T,. Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006; 13: 1235-1242.
2. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, Frank DA,. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 2009; 7: 966-976.
3. Lin TS, Mahajan S, Frank DA,. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000; 19: 2496-2504.
4. Turkson J, Jove R,. STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-6626.
5. Zhong Z, Wen Z, Darnell JE Jr,. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264: 95-98.
6. Ruff-Jamison S, Zhong Z, Wen Z, Chen K, Darnell JE Jr, Cohen S,. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J Biol Chem 1994; 269: 21933-21935.
7. Darnell JE Jr, Kerr IM, Stark GR,. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
8. Heinrich PC, Horn F, Graeve L, Dittrich E, Kerr I, Müller-Newen G, Grötzinger J, Wollmer A,. Interleukin-6 and related cytokines: Effect on the acute phase reaction. Z Ernahrungswiss 1998; 37 (Suppl 1): 43-49.
9. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y,. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006; 203: 1651-1656.
10. Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, Kortylewski M, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H,. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005; 174: 3925-3931.
11. Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludag H,. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 2010; 31: 1420-1428.
12. Yu H, Jove R,. The STATs of cancer-New molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
13. Wojcik EJ, Sharifpoor S, Miller NA, Wright TG, Watering R, Tremblay EA, Swan K, Mueller CR, Elliott BE,. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006; 25: 2773-2784.
14. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S,. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 3550-3560.
15. Yu H, Kortylewski M, Pardoll D,. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
16. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM,. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-1279.
17. Bharti AC, Donato N, Aggarwal BB,. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863-3871.
18. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R,. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
19. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R,. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001; 276: 45443-45455.
20. Turkson J, Zhang SM, Mora LB, Burns A, Sebti S, Jove R,. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005; 280: 32979-32988.
21. Liu X, Li J, Zhang J,. STAT3-decoy ODN inhibits cytokine autocrine of murine tumor cells. Cell Mol Immunol 2007; 4: 309-313.
22. Yue P, Turkson J,. Targeting STAT3 in cancer: How successful are we? Expert Opin Investig Drugs 2009; 18: 45-56.
23. Wang Z, Rao DD, Senzer N, Nemunaitis J,. RNA interference and cancer therapy. Pharm Res 2011; 28: 2983-2995.
24. Falamarzian A, Xiong XB, Uludag H, Lavasanifar A,. Polymeric micelles for siRNA delivery. J Drug Deliv Sci Technol 2012; 22: 43-54.
25. Shim MS, Kwon YJ,. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010; 277: 4814-4827.
26. Kim SS, Garg H, Joshi A, Manjunath N,. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med 2009; 15: 491-500.
27. Dykxhoorn DM, Palliser D, Lieberman J,. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006; 13: 541-552.
28. Xiong XB, Uludag H, Lavasanifar A,. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 2009; 30: 242-253.
29. Edelstein ML, Abedi MR, Wixon J,. Gene therapy clinical trials worldwide to 2007-An update. J Gene Med 2007; 9: 833-842.
30. Couto LB, High KA,. Viral vector-mediated RNA interference. Curr Opin Pharmacol 2010; 10: 534-542.
31. Putnam D,. Polymers for gene delivery across length scales. Nat Mater 2006; 5: 439-451.
32. Gunther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A,. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 2011; 77: 438-449.
33. Grayson AC, Doody AM, Putnam D,. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 2006; 23: 1868-1876.
34. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-7301.
35. Aigner A,. Gene silencing through RNA interference (RNAi) in vivo: Strategies based on the direct application of siRNAs. J Biotechnol 2006; 124: 12-25.
36. Neamnark A, Suwantong O, Bahadur RK, Hsu CY, Supaphol P, Uludag H,. Aliphatic lipid substitution on 2 kDa polyethylenimine improves plasmid delivery and transgene expression. Mol Pharm 2009; 6: 1798-1815.
37. Aliabadi HM, Landry B, Bahadur RK, Neamnark A, Suwantong O, Uludag H,. Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers. Macromol Biosci 2011; 11: 662-672.
38. Aliabadi HM, Landry B, Mahdipoor P, Hsu CY, Uludag H,. Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. Eur J Pharm Biopharm 2012; 81: 33-42.
39. Incani V, Tunis E, Clements BA, Olson C, Kucharski C, Lavasanifar A, Uludag H,. Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells. J Biomed Mater Res A 2007; 81: 493-504.
40. Silva CM,. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017-8023.
41. Darnell JE,. Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595-596.
42. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E,. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 2007; 258: 181-188.
43. Barre B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O,. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007; 13: 4-11.
44. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K,. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735.
45. Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R,. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004; 3: 261-269.
46. Song H, Wang R, Wang S, Lin J,. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005; 102: 4700-4705.
47. Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R,. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004; 3: 1533-1542.
48. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR,. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100: 4138-4143.
49. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A,. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther 2004; 3: 1183-1191.
50. Ling X, Arlinghaus RB,. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005; 65: 2532-2536.
51. Zhou W, Grandis JR, Wells A,. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br J Cancer 2006; 95: 164-171.
52. Zhang Y, Zhang JW, Lv GY, Xie SL, Wang GY,. Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells. Int J Med Sci 2012; 9: 216-224.
53. Incani V, Lavasanifar A, Uludag H,. Lipid and hydrophobic modification of cationic carriers on route to superior gene vectors. Soft Matter 2010; 6: 2124-2138.
54. Clevenger CV,. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004; 165: 1449-1460.
55. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL,. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002; 21: 7611-7618.
56. Kim J, Lee YJ, Shin DS, Jeon SH, Son KH, Han DC, Jung SN, Oh TK, Kwon BM,. Cosmomycin C inhibits signal transducer and activator of transcription 3 (STAT3) pathways in MDA-MB-468 breast cancer cell. Bioorg Med Chem 2011; 19: 7582-7589.
57. Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, Liu Z, Ding Y, Wang B, Mælandsmo GM, Nesland JM, Fodstad O, Tan M,. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther 2011; 10: 960-971.
58. Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS,. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol 2009; 34: 1209-1220.
59. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL,. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012; 52: 1213-1225.
60. Shahin M, Lavasanifar A,. Novel self-associating poly(ethylene oxide)-b-poly(epsilon-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery. Int J Pharm 2010; 389: 213-222.